Nilotinib
- Generic Name
- Nilotinib
- Brand Names
- Tasigna, Nilotinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22F3N7O
- CAS Number
- 641571-10-0
- Unique Ingredient Identifier
- F41401512X
- Background
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
- Indication
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Refractory Gastrointestinal stromal tumor
- Associated Therapies
- -
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-05-03
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 507
- Registration Number
- NCT00109707
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Div.of Hematologic Malignancie, Baltimore, Maryland, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸University of Chicago Medical Center Dept. of U. of Chicago Hosp(3), Chicago, Illinois, United States
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
- Conditions
- Recurrent Adult Acute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic PhaseChildhood Acute Lymphoblastic Leukemia in RemissionChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent DiseaseAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chronic Phase of Disease
- Interventions
- Drug: CyclosporineDrug: DasatinibDrug: Fludarabine PhosphateDrug: Imatinib MesylateDrug: Mycophenolate MofetilDrug: NilotinibProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationBiological: Therapeutic Allogeneic LymphocytesRadiation: Total-Body Irradiation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00036738
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.